Aim: The study aimed to evaluate the effectiveness of hydrodilatation in treating primary frozen shoulder by assessing improvements in functional range of motion (ROM), pain intensity using the Visual Analogue Scale (VAS), and disability through the Shoulder Pain and Disability Index (SPADI) score. Materials and Methods: Twenty-five patients aged 30-70 years with first-time diagnoses of primary frozen shoulder, experiencing shoulder pain and reduced shoulder motion (flexion, abduction, and external rotation) for at least one month, were included. Exclusion criteria encompassed patients with hematologic disorders, autoimmune diseases, previous shoulder surgeries, infections, fractures, neuromuscular diseases, or those on anticoagulant therapy.Patients underwent hydrodilatation with a mixture of 5 mL 1% lignocaine, 1 mL triamcinolone (40 mg), and 40 mL normal saline. Evaluations were conducted immediately after injection, and again at 1 week, 1 month, and 6 months post-treatment, measuring ROM, VAS, and SPADI scores. Results: Statistical analysis showed significant improvements in shoulder ROM, along with decreased VAS and SPADI scores, at all follow-up intervals (p < 0.001), indicating reduced pain and improved shoulder function. Conclusion: Hydrodilatation proved to be a safe, effective, and cost-efficient treatment for primary adhesive capsulitis, demonstrating marked improvements in patient outcomes. However, further multi-centric studies are recommended to explore the long-term efficacy of hydrodilatation compared to alternative treatments.